Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma

Background: The approval of immune checkpoint inhibitors in combination with specific diagnostic biomarkers presents new challenges to pathologists as tumor tissue needs to be tested for expression of programmed death-ligand 1 (PD-L1) for a variety of indications. As there is currently no requiremen...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Julika Ribbat-Idel, Franz F. Dressler, Rosemarie Krupar, Christian Watermann, Finn-Ole Paulsen, Patrick Kuppler, Luise Klapper, Anne Offermann, Barbara Wollenberg, Dirk Rades, Simon Laban, Markus Reischl, Karl-Ludwig Bruchhage, Christian Idel, Sven Perner
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2021-04-01
Edice:	Frontiers in Medicine
Témata:	HNSCC PD-L1 checkpoint inhibitors TMA harmonization therapy prediction
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fmed.2021.640515/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!